The study that was done by Oliver Wyman, which Madam Vice-Chair referred to, looked at manufacturing capacity, and it divided it into several subcategories. But perhaps the most relevant one to your question is that some of the production facilities are certified GMP, which means they are certified by the Canadian and U.S. regulatory agencies as producing product that can be used in human trials. Even not considering those facilities that are non-GMP certified, there was excess capacity.
The study also only looked at production capacity in Europe and North America. It didn't look at the rapidly growing production capacity in India that was referred to by Ms. Medwick, or in China, for example, nor did it look at the production capacity in the large pharmaceutical manufacturers. So we believe that just by looking at the GMP-certified production capacity, there was sufficient production capacity, without even considering whether the non-GMP could be brought up to snuff.